Angiogenesis inhibitors for the treatment of epithelial ovarian cancer

Gaitskell, Kezia; Rogozińska, Ewelina; Platt, Sarah; Chen, Yifan; Aziz, Mohamed Abd El; Tattersall, Abigail; Morrison, Jo

doi:10.1002/14651858.cd007930.pub3

Cited by 4 publications

(1 citation statement)

References 263 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian serous cystadenocarcinoma (OSC), the most prevalent histotype of ovarian cancer, diverges in genomic characteristics from endometrioid, clear cell, and mucinous ovarian cancer. The advent of an array of novel therapeutic agents in recent years, including angiogenesis inhibitors 19 , 20 , PARP inhibitors 21 , 22 , cell cycle checkpoint inhibitors 23 , 24 , and immune checkpoint inhibitors 25 , 26 , has paved the way for innovative approaches to ovarian cancer treatment, offering a glimmer of hope for extending patient survival. It is crucial to underscore that the substantial advancements in these treatment modalities predominantly apply to OSC.…”

Section: Discussionmentioning

confidence: 99%

Abnormal expressions of PURPL, miR-363-3p and ADAM10 predicted poor prognosis for patients with ovarian serous cystadenocarcinoma

Zhang,

Guo,

Zhao

et al. 2023

J. Cancer

View full text Add to dashboard Cite

Objective: This study aimed to elucidate the prognostic implications of deviant expressions of long non-coding RNA (lncRNA) p53 upregulated regulator of p53 levels (PURPL), microRNA-363-3p (miR-363-3p), and ADAM metallopeptidase domain 10 (ADAM10) in patients diagnosed with ovarian serous cystadenocarcinoma (OSC). Methods: To predict and refine the targeted miRNAs and downstream target genes for PURPL, we utilized open medical databases. Through the employment of real-time RT-PCR, we conducted tissue analysis to discern the expressions of PURPL, miR-363-3p, and ADAM10 in both OSC and control tissues. The pathological correlations in the clinic and the prognostic implications of deviant expressions of PURPL, miR-363-3p, and ADAM10 in OSC patients were analyzed independently. Results: Database inquiries revealed that PURPL might target miR-363-3p, and in turn, miR-363-3p could target ADAM10. Differential expression of PURPL, miR-363-3p, and ADAM10 was observed between OSC and paired tissues. The premature version of miR-363-3p, miR-363, correlated with overall survival (OS), while ADAM10 corresponded with progression-free survival (PFS) in ovarian cancer patients. Tissue detection displayed significantly elevated expressions of PURPL and ADAM10, and conspicuously diminished expressions of miR-363-3p in OSC tissues compared to the control tissues (P<0.05). A negative correlation was observed between the expressions of PURPL and miR-363-3p, and miR-363-3p and ADAM10, while a positive correlation was found between PURPL and ADAM10 in different ovarian tissues (P<0.05). In OSC tissues, upregulation of PURPL was associated with an advanced clinical stage, TP53 mutation, and lymph node metastasis (P<0.05), downregulation of miR-363-3p was associated with a more advanced clinical stage and lymph node metastasis (P<0.05), and overexpression of ADAM10 correlated with a more advanced FIGO stage. High expressions of PURPL and ADAM10, and low expression of miR-363-3p, were linked with poor PFS and OS in OSC patients, respectively (P<0.05). In addition, OSC patients with elevated PURPL and reduced miR-363-3p, patients with elevated PURPL and ADAM10, and patients with reduced miR-363-3p and elevated ADAM10 also demonstrated worse PFS and OS, respectively (P<0.05). Conclusions: The anomalous expressions of PURPL, miR-363-3p, and ADAM10 might contribute to the pathogenesis of OSC via up-down stream regulation, and these abnormal expressions could serve as potential prognostic indicators for OSC patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Abnormal expressions of PURPL, miR-363-3p and ADAM10 predicted poor prognosis for patients with ovarian serous cystadenocarcinoma

Zhang,

Guo,

Zhao

et al. 2023

J. Cancer

View full text Add to dashboard Cite

show abstract

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

Newhouse

Nelissen

El-Shakankery

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundCancer of ovarian, fallopian tube and peritoneal origin, referred to collectively as ovarian cancer, is the eighth most common cancer in women and is o en diagnosed at an advanced stage. Women with relapsed epithelial ovarian cancer (EOC) are less well and have a limited life expectancy, therefore maintaining quality of life with e ective symptom control is an important aim of treatment. However, the unwanted e ects of chemotherapy agents may be severe, and optimal treatment regimens are unclear. Pegylated liposomal doxorubicin (PLD), which contains a cytotoxic drug called doxorubicin hydrochloride, is one of several treatment modalities that may be considered for treatment of relapsed EOCs. This is an update of the original Cochrane Review which was published in Issue 7, 2013. ObjectivesTo evaluate the e icacy and safety of PLD, with or without other anti-cancer drugs, in women with relapsed high grade epithelial ovarian cancer (EOC). Search methodsWe searched CENTRAL, MEDLINE (via Ovid) and Embase (via Ovid) from 1990 to January 2022. We also searched online registers of clinical trials, abstracts of scientific meetings and reference lists of included studies. Selection criteriaWe included randomised controlled trials (RCTs) that evaluated PLD in women diagnosed with relapsed epithelial ovarian cancer. Data collection and analysisTwo review authors independently extracted data to a pre-designed data collection form and assessed the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions guidelines. Where possible, we pooled collected data in meta-analyses. Main resultsThis is an update of a previous review with 12 additional studies, so this updated review includes a total of 26 RCTs with 8277 participants that evaluated the e ects of PLD alone or in combination with other drugs in recurrent EOC: seven in platinum-sensitive disease (2872 participants); 11 in platinum-resistant disease (3246 participants); and eight that recruited individuals regardless of platinum sensitivity status (2079 participants). The certainty of the evidence was assessed for the three most clinically relevant comparisons out of eight comparisons identified in the included RCTs. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer (Review)

show abstract

British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024

Moss,

Taylor,

Andreou

et al. 2024

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer

Abstract: Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 4, 2023.

Cited by 4 publications

References 263 publications

Abnormal expressions of PURPL, miR-363-3p and ADAM10 predicted poor prognosis for patients with ovarian serous cystadenocarcinoma

Abnormal expressions of PURPL, miR-363-3p and ADAM10 predicted poor prognosis for patients with ovarian serous cystadenocarcinoma

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024

Contact Info

Product

Resources

About